Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ibritumomab tiuxetan + rituximab + carmustine + cytarabine + etoposide + melphalan
- Development stage
- Phase 3
- Lead developer
- Biogen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy used in the treatment of relapsed or refractory lymphoma, particularly B-cell non-Hodgkin lymphoma. It combines the radioimmunotherapeutic agent ibritumomab tiuxetan (Zevalin), the monoclonal antibody rituximab, and the chemotherapy agents carmustine, etoposide, cytarabine, and melphalan (collectively known as BEAM). This regimen is typically used as a conditioning regimen before autologous hematopoietic cell transplantation. The combination of rituximab with BEAM is known as R-BEAM, while the combination of ibritumomab tiuxetan with BEAM is known as B-BEAM.
- Other names
- B-BEAMR-BEAM
02
Targets
Beyond the preview
Go deeper on ibritumomab tiuxetan + rituximab + carmustine + cytarabine + etoposide + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ibritumomab tiuxetan + rituximab + carmustine + cytarabine + etoposide + melphalan.